[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,326,908
  • Shares Outstanding, K 199,782
  • Annual Sales, $ 5,141 M
  • Annual Income, $ 1,287 M
  • EBIT $ 1,611 M
  • EBITDA $ 1,704 M
  • 60-Month Beta 0.79
  • Price/Sales 3.79
  • Price/Cash Flow 15.77
  • Price/Book 3.46

Options Overview Details

View History
  • Implied Volatility 36.11% (-1.04%)
  • Historical Volatility 23.04%
  • IV Percentile 41%
  • IV Rank 28.13%
  • IV High 64.77% on 10/31/25
  • IV Low 24.90% on 08/08/25
  • Expected Move (DTE 19) 6.55 (6.77%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 323
  • Volume Avg (30-Day) 300
  • Put/Call OI Ratio 1.19
  • Today's Open Interest 15,951
  • Open Int (30-Day) 15,618
  • Expected Range 90.20 to 103.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.60
  • Number of Estimates 7
  • High Estimate $1.73
  • Low Estimate $1.38
  • Prior Year $1.31
  • Growth Rate Est. (year over year) +22.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
94.10 +2.81%
on 05/19/26
103.01 -6.09%
on 05/11/26
-2.36 (-2.38%)
since 04/29/26
3-Month
89.25 +8.39%
on 03/24/26
103.01 -6.09%
on 05/11/26
-4.53 (-4.47%)
since 02/27/26
52-Week
63.92 +51.33%
on 06/02/25
112.29 -13.85%
on 01/07/26
+31.81 (+48.99%)
since 05/28/25

Most Recent Stories

More News
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi ® /Minjuvi ® ) and lenalidomide in addition to R-CHOP, the current standard of care, compared with...

INCY : 96.74 (-0.78%)
3 Profitable Stocks for Long-Term Investors

3 Profitable Stocks for Long-Term Investors

AZO : 2,935.19 (-2.39%)
INCY : 96.74 (-0.78%)
AMG : 302.85 (-0.04%)
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 47 th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. EDT. The...

INCY : 96.74 (-0.78%)
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out

Incyte (NASDAQ:INCY) Chief Medical Officer Steven Stein outlined the company’s development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody 989,...

INCY : 96.74 (-0.78%)
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

The expanded agreement is one of the first major Pharma-AI collaborations to power large-scale foundation model training with a partner's proprietary experimental data ...

INCY : 96.74 (-0.78%)
Incyte Stock: Analyst Estimates & Ratings

As Incyte has considerably outperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

$SPX : 7,580.06 (+0.22%)
IBB : 172.18 (-0.03%)
INCY : 96.74 (-0.78%)
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development

Incyte (Nasdaq:INCY) and Edison Scientific today announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for Incyte’s discovery and development work. This press...

INCY : 96.74 (-0.78%)
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build

Incyte (NASDAQ:INCY) President and CEO Bill Meury said the company’s post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business,...

INCY : 96.74 (-0.78%)
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

Data from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi ® /Minjuvi ® ) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious...

INCY : 96.74 (-0.78%)
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs)...

INCY : 96.74 (-0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 99.52
2nd Resistance Point 98.76
1st Resistance Point 97.75
Last Price 96.74
1st Support Level 95.98
2nd Support Level 95.22
3rd Support Level 94.21

See More

52-Week High 112.29
Last Price 96.74
Fibonacci 61.8% 93.81
Fibonacci 50% 88.11
Fibonacci 38.2% 82.40
52-Week Low 63.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.